ES2668045T3 - Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas - Google Patents
Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas Download PDFInfo
- Publication number
- ES2668045T3 ES2668045T3 ES13811325.3T ES13811325T ES2668045T3 ES 2668045 T3 ES2668045 T3 ES 2668045T3 ES 13811325 T ES13811325 T ES 13811325T ES 2668045 T3 ES2668045 T3 ES 2668045T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- comp
- cells
- alkyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una composición que comprende un excipiente farmacéuticamente aceptable y un compuesto que tiene una estructura de fórmula (I): **(Ver fórmula)** o una sal, estereoisómero, tautómero, hidrato o solvato farmacéuticamente aceptable de estos, en donde: R1 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo; R2 es una porción no glicomimética enlazadora, en donde la porción no glicomimética comprende polietilenglicol; R3 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo, C2-C8 haloalquinilo o ciclopropilo; R4 es -OH o -NZ1Z2 donde Z1 y Z2 son cada uno independientemente H, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8haloalquenilo o C2-C8 haloalquinilo o en donde Z1 y Z2 se unen para formar un anillo; R5 es C3-C8 cicloalquilo; R6 es -OH, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo; R7 es -CH2OH, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo; y R8 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo para su uso en un método para movilizar células de la médula ósea en un sujeto.
Description
5
10
15
20
25
30
35
40
45
50
55
60
65
DESCRIPCION
Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
Antecedentes
Campo técnico
Los agentes y sus composiciones que se describen en la presente descripción son antagonistas de la E-selectina y pueden usarse como terapéuticos. Se describen los métodos para movilizar células de la médula ósea mediante el uso de los antagonistas de la E-selectina descritos en la presente descripción.
Descripción de la Técnica Relacionada
El trasplante autólogo de células madre hematopoyéticas (HSCT) es un enfoque terapéutico curativo potencialmente para diferentes enfermedades hematológicas y linfoides malignas. Las células madre hematopoyéticas (HSC) pueden recolectarse de la sangre o la médula ósea y usarse para repoblar la hematopoyesis. Estudios recientes demuestran las ventajas clínicas de volver a infundir células madre de sangre periférica movilizadas autólogas en comparación con las HSC de médula ósea (ver, por ejemplo, Lemoli y otros, Haematologica 93:321-324 (2008); Gratwohl y otros, Blood 100:2374-86 (2002)). La citocina, factor estimulante de colonias de granulocitos (G-CSF), ha sido el agente que se usa predominantemente en la clínica para la movilización de las HSC. Más recientemente, un antagonista del receptor 4 (CXCR4) de la quimiocina (motivo C-X-C), AMD3100 (llamado además plerixafor) se ha administrado solo o con G-CSF para este propósito.
No todos los pacientes tratados con G-CSF tienen una movilización exitosa de células madre de sangre periférica: hasta un 25% de pacientes con linfomas, mieloma múltiple o leucemia aguda, y en 10-20% de voluntarios normales, todos los que requieren aféresis extendidos (ver, por ejemplo, Pelus, Curr. Opin. Hematol. 15:285-92 (2008) y referencias citadas en el lugar). Se están realizando estudios para identificar agentes adicionales para usarse solos o en combinación con G-CSF para reducir el requisito de multidosis y mejorar la calidad de vida a largo plazo.
Por lo tanto, existe una necesidad en la técnica de identificar terapias altamente eficaces, no tóxicas y menos costosas útiles para movilizar las células madre de sangre periférica.
El documento de patente núm. WO 2012/061662 describe compuestos peptidomiméticos glicomiméticos que inhiben las E-selectinas y los receptores de quimiocina CXCR4, que son útiles para tratar el cáncer y las enfermedades inflamatorias, y para liberar células tales como células madre en sangre circulante y mejorar la retención de las células en la sangre. El documento de patente núm. WO 2013/096926 describe los antagonistas de la E-selectina que son útiles en los métodos para el tratamiento de cánceres, y el tratamiento y la prevención de la metástasis, la inhibición de la infiltración de las células cancerosas en la médula ósea, al reducir o inhibir la adhesión de las células cancerosas a las células endoteliales que incluyen las células en la médula ósea y la inhibición de la formación de trombos.
Breve descripción
Brevemente, en la presente descripción se proporcionan agentes que son antagonistas de la E-selectina, composiciones que comprenden los agentes y métodos para usar los agentes. Estos agentes son útiles para movilizar las células de la médula ósea, que incluyen las células hematopoyéticas, tales como, células madre hematopoyéticas y células progenitoras y glóbulos blancos, tales como granulocitos (que incluyen neutrófilos). En otras modalidades, las células son células tumorales tales como las células tumorales malignas o las células tumorales hematológicas. Los compuestos glicomiméticos que pueden usarse en estos métodos son antagonistas de la E-selectina como se describe en la presente descripción.
En una modalidad, la Modalidad I, una composición que comprende un excipiente aceptable farmacéuticamente y un compuesto, se proporciona para su uso en un método de movilizar células de la médula ósea en un sujeto. El compuesto (que es un compuesto glicomimético que es un antagonista de la E-selectina) tiene la siguiente fórmula (I):
5
10
15
20
25
30
35
40
45
50
55
60
65
o una sal aceptable farmacéuticamente, isómero, tautómero, hidrato o solvato de éste, en donde:
R1 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo;
R2 es una porción no glicomimética enlazadora, en donde la porción no glicomimética comprende polietilenglicol;
R3 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo, C2-C8 haloalquinilo o
ciclopropilo;
R4 es -OH o -NZ1Z2 donde Z1 y Z2 son cada uno independientemente H, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8haloalquenilo o C2-C8 haloalquinilo o en donde Z1 y Z2 se unen para formar un anillo;
R5 es C3-C8 cicloalquilo;
R6 es -OH, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo;
R7 es -CH2OH, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8haloalquilo, C2-C8 haloalquenilo o C2-C8
haloalquinilo; y
R8 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo.
Modalidad 2: La composición de la Modalidad 1 para su uso, en donde, (a) al menos uno de R1, R3, R6, R7 y R8 es C1-C8 haloalquilo; (b) al menos uno de R3, R6, R7 y R8 es C1-C8 haloalquilo; (c) al menos dos de R1, R3, R6, R7 y R8 son C1-C8 haloalquilo; (d) R2 es una porción no glicomimética enlazadora; o (e) al menos uno de R1, R3, R6, R7 y R8 es C1-C8 haloalquilo, y R2 es una porción no glicomimética enlazadora.
Modalidad 3: La composición de la Modalidad 1 o la Modalidad 2 para su uso, en donde, cada C1-C8 haloalquilo se selecciona independientemente de -CH2X, CH2-(CH2)m- CH2X, CHX2, -CH2-(CH2)m- CHX2, -CX3 y -CH2-(CH2)m-CX3, en donde, m es 0-6 y X es F, Cl, Br o I. Modalidad 4: La composición de la Modalidad 3 para su uso, en donde, al menos una X es F. Modalidad 5. La composición de la Modalidad 3 para su uso, en donde, al menos un C1-C8 haloalquilo es - CH2X, -CHX2 o -CX3. Modalidad 6: La composición de la Modalidad 5 para su uso, en donde, al menos X es F.
Modalidad 7: La composición de cualquiera de las Modalidades 1-3 para su uso, en donde R4 es -OH o -NZ1Z2 en donde Z1 y Z2 son cada C1-C8 alquilo. Modalidad 8: La composición de la Modalidad 7 para su uso, en donde, Z1 y Z2 son cada-CH3.
Modalidad 9: La composición de cualquiera de las Modalidades 1-8 para su uso, en donde, R7 es -CH2OH, C1-C8 alquilo, C1-C8 haloalquilo. Modalidad 10: La composición de la Modalidad 9 para su uso, en donde, R7es -CH2OH o -CHF2.
Modalidad 11: La composición de cualquiera de las Modalidades 1-10 para su uso, en donde, R3 es C1-C8 alquilo, C1-C8 haloalquilo, o ciclopropilo. Modalidad 12: La composición de la Modalidad 11 para su uso, en donde, R3 es metilo o trifluorometilo.
Modalidad 13: La composición de cualquiera de las Modalidades 1-12 para su uso, en donde, R8 es C1-C8 alquilo, C1-C8 haloalquilo. Modalidad 14: La composición de la Modalidad 13 para su uso, en donde, R8es metilo o trifluorometilo.
Modalidad 15: La composición de cualquiera de las Modalidades 1-14 para su uso, en donde, R6 es -OH.
Modalidad 16: La composición de cualquiera de las Modalidades 1-15 para su uso, en donde R5 es ciclohexilo.
Modalidad 17: La composición de cualquiera de las Modalidades 1-16 para su uso, en donde, R1 es C1-C8 alquilo o C1- C8 haloalquilo. Modalidad 18: La composición de la Modalidad 17 para su uso, en donde, R1es etilo o -CHF2.
Modalidad 19: La composición de cualquiera de las Modalidades 1-18 para su uso, en donde, el compuesto de fórmula (I) tiene una estructura de la fórmula (Ia):
5
10
15
20
25
30
35
40
45
50
55
60
65
en donde R1 es C1-C8 alquilo o C1-C8 haloalquilo;
R2 es una porción no glicomimética enlazadora, en donde la porción no glicomimética comprende polietilenglicol;
R3 es C1-C8 alquilo, C1-C8 haloalquilo, o ciclopropilo;
R4 es -OH o -NZ1Z2 donde Z1 y Z2 son cada uno independientemente H o C1-C8 alquilo;
R7 es -CH2OH, C1-C8 alquilo, C1-C8 haloalquilo, y
R8 es C1-C8 alquilo o C1-C8 haloalquilo. Modalidad 20: La composición de la Modalidad 19 para su uso, en donde, halo es F.
Modalidad 21: La composición de la Modalidad 19 o la Modalidad 20 para su uso, en donde, R1 es -CH3, -CH2CH3, - CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, o -CH2CF3.
Modalidad 22: La composición de cualquiera de las Modalidades 19-21 para su uso, en donde, R3 es -CH3, -CH2F, - CHF2, o -CF3.
Modalidad 23: La composición de cualquiera de las Modalidades 19-22 para su uso, en donde R4 es -OH o -N(CH3)2.
Modalidad 24: La composición de cualquiera de las Modalidades 19-23 para su uso, en donde R7 es -CH2OH, -CH3, - CH2F, -CHF2, o -CF3.
Modalidad 25: La composición de cualquiera de las Modalidades 19-24 para su uso, en donde, R8 es -CH3, -CH2F, - CHF2, o -CF3.
Modalidad 26: La composición de cualquiera de las Modalidades 1-25 para su uso, en donde, R2 es una porción no glicomimética enlazadora, y en donde, la poción no glicomimética comprende polietilenglicol, y en donde, el compuesto de la fórmula (I) tiene una de las fórmulas (Ib) o (Ic) descritas en la presente descripción.
o
5
10
15
20
25
30
35
40
45
50
55
60
65
en donde n es 1 a 100. Modalidad 27: La composición de la Modalidad 26 para su uso, en donde, n es 4, 8, 12, 16, 20, 24, o 28.
Modalidad 28 y Modalidad 29: La composición de la Modalidad 26 o la Modalidad 27 para su uso, en donde, el compuesto tiene una de las fórmulas:
o
Modalidad 30: La composición de la Modalidad 1 o la Modalidad 19 para su uso, en donde, el compuesto de la fórmula (I) tiene una de las fórmulas: (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), o (Ik) descritas en la presente descripción.
Modalidad 31: La composición de la Modalidad 1 para su uso, en donde, el compuesto de fórmula (I) tiene una de las fórmulas específicas, que se describen en la presente descripción. Ejemplos de tales compuestos incluyen los siguientes:
Claims (9)
- 5101520253035404550556065Reivindicaciones1. Una composición que comprende un excipiente farmacéuticamente aceptable y un compuesto que tiene una estructura de fórmula (I):
imagen1 o una sal, estereoisómero, tautómero, hidrato o solvato farmacéuticamente aceptable de estos, en donde:R1 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo o C2-C8haloalquinilo;R2 es una porción no glicomimética enlazadora, en donde la porción no glicomimética comprendepolietilenglicol;R3 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo, C2-C8 haloalquinilo o ciclopropilo;R4 es -OH o -NZ1Z2 donde Z1 y Z2 son cada uno independientemente H, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8haloalquenilo o C2-C8 haloalquinilo o en donde Z1 y Z2 se unen para formar un anillo;R5 es C3-C8 cicloalquilo;R6 es -OH, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8haloalquilo, C2-C8 haloalquenilo o C2-C8haloalquinilo;R7 es -CH2OH, C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8haloalquilo, C2-C8 haloalquenilo o C2-C8 haloalquinilo; yR8 es C1-C8 alquilo, C2-C8 alquenilo, C2-C8 alquinilo, C1-C8 haloalquilo, C2-C8 haloalquenilo o C2-C8haloalquinilopara su uso en un método para movilizar células de la médula ósea en un sujeto. - 2. La composición para su uso de acuerdo con la reivindicación 1 en donde el compuesto de la fórmula (I) tiene la fórmula:
imagen2 imagen3 5 4.10 15 - 5.202530
- 6. 3540en donde n es 1 a 100.La composición para su uso de acuerdo con la reivindicación 2, en donde n es 4, 8, 12, 16, 20, 24 o 28. La composición para su uso de acuerdo con la reivindicación 1, en donde el compuesto tiene la fórmula:
imagen4 La composición para su uso de acuerdo con la reivindicación 1, en donde el compuesto tiene la fórmula:imagen5 La composición para su uso de acuerdo con la reivindicación 1, en donde el compuesto tiene la fórmula:imagen6 45 7.5055La composición para su uso de acuerdo con la reivindicación 1, en donde el compuesto tiene la fórmula:imagen7 60 8. 9.La composición para su uso de acuerdo con cualquiera de las reivindicaciones 1-7, en donde las células son células hematopoyéticas.La composición para su uso de acuerdo con la reivindicación 8, en donde las células hematopoyéticas son células madre hematopoyéticas y células progenitoras hematopoyéticas. -
- 10.
- La composición para su uso de acuerdo con la reivindicación 8, en donde las células hematopoyéticas son glóbulos blancos maduros.
-
- 11. 5
- La composición para su uso de acuerdo con cualquiera de las reivindicaciones 1-7, en donde las células son células tumorales.
-
- 12.
- La composición para su uso de acuerdo con la reivindicación 11, en donde las células tumorales son células tumorales hematológicas.
- 10 13.
- La composición para su uso de acuerdo con la reivindicación 11, en donde las células tumorales son células malignas.
imagen8 sttWlI Ofin, 7-4^7^ ch• K)M80m*. jNO□ M1 etapa (Formación declonante2 etapas (Fucosilacion ytricloroacetamidato)eliminación de TBDMS iOC-N-l/LC^j>' .'II QAoD i I1 etapa (Formación de2 etapas (Glicosidacion y deacetilacion)donante tnflato)«etapa (Benzoilacíon selectiva en6-OH de GalN-deriv)1 etapa (Acoplamiento)1 etapa (Transformación de aliloxia N-acetilo)2 etapas(Hidrogenaciony debenzoilacion)Compuesto 22Figura 1Aimagen9 V. NaHCOj. KM2. H20DBU, THFNaHCO,. MeOHRacemicoAgitar, t.a, toda la noche, Reflujo toda la noche• • IReflujo, 3h,OAcNovozyme 435, Vinilacetato,OH t-BuOMeMeOMeOAgitar, t.a50-62*40-4 5%>95% eeTBDMS-CI, DBU,Agitar, toda la noche, t.aOTBDMSOTBOMSMCPBA, DCMMaCMeOAgitar, toda la nocheCuCN, TetravlnilestarionBuLi. BFj-eterato, THF78 a -20 gradosAgitar. 4hO MeTBSOFigura 1Bimagen10 sn1O eni !.Br2. CH2CI2DMACiclohexanoub-2- BujNBr, CHjClc, DMF03ncrvi3-BuiNF. THFSíntesis del compuesto 141. Cloroformiato de aillo, NaOMe °/VÍ'Jr*oDBU.CCIjCN Ch2D2CIKjMMeOH,TE ANhUOAc, DMF'RfOH 2-Py/ACiONG'RfE M' OAcF 'AeOi -iOAC/Níiir- o1 OAcOC(=NH|CCIs.3. 1 'OAcSintesis del compuesto 20'Rf. - 3.CN. CHjCNA QOM«DIA OMNaOMe-MeOHBFj-EteratoOAc IOAcOBnOBnOBnOBI' B .OOn>OM»OMt 1. BihSnO. MeOH'Rt°rr'RT°RRHOBcCN.CHjCN ho2 o OBrOOzOhDB013 nOBI»r-iOB"JLn_ L‘.CsF, dinietoxietanoO OBn O>-q^l8 Pd(Ph)4 BujSnFi.Ac20, CH2CI20\1eRf°R£°OOt■-•I-OGlBUOHcun1 H I,OBnllrFigura 1C
imagen11 o oh oVom. Hs/IOSPd-CMaOMe MeOHiRTDioxano-H20-AcOHOB z II r\u0620*ÜHomL.ML ó'00"OM«1 OHOHi'MSíntesis del compuesto 25iRf°^NI1?OH1 OHSHNDMF TEAINSTP=?5OH' OHFigura 1Do.OBnO,OBn05imagen12 OBo °'imagen13 coowe pd-trifenil fosfinaBu3SnH, (CF3C0)20imagen14 HN^CF3imagen15 imagen16 46-102.imagen17 Figura 3AFigura 3Bñenboenen'enfsjlr~imagen18 imagen19 imagen20 imagen21 imagen22 - 3.9254^COCT>r— cp coI40 00 £2 2? 2 S gooocsj r—CO CO co co cococoCNJ$\ss\\7/oococococoCO CO CO coLOcoLOco3>co .ooCVJcoIr—co
- *—
- r-
- 04
- CNj cvi
- co
- CO
- co
- co
- CNJ
- 00 a S8
- CO
- co
- CO
- \
- \ - I
imagen23 Figura 3Dosimagen24 6532imagen25 Neutrófilos (K/pl)Movilización de Neutrófilosimagen26 HorasWBCenNJimagen27 2hrs 3hrs 6hrs---------Comp. 25 (60)-----------Comp. 25 (40)-----------Comp. 25 (20)-------ControlNeutrófilosencoimagen28 ---------Comp. 25 (60)-----------Comp. 25 (40)---------Comp. 25 (20)-------ControlComp.Eosinófilosimagen29 ---------Comp. 25 (60)----------Comp. 25 (40)---------Comp. 25(20)-------ControlLinfocitosimagen30 ---------Comp. 25 (60)-----------Comp. 25 (40)----------Comp. 25 (20)-------ControlenCT>Monocitosimagen31 -------AMD3100---------Comp. 25 (60)-----------Comp. 25 (40)---------Comp. 25 (20)-------Control
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261734924P | 2012-12-07 | 2012-12-07 | |
US201261734924P | 2012-12-07 | ||
US201361784206P | 2013-03-14 | 2013-03-14 | |
US201361784206P | 2013-03-14 | ||
PCT/US2013/073258 WO2014089269A1 (en) | 2012-12-07 | 2013-12-05 | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2668045T3 true ES2668045T3 (es) | 2018-05-16 |
Family
ID=49841843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13811325.3T Active ES2668045T3 (es) | 2012-12-07 | 2013-12-05 | Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas |
Country Status (15)
Country | Link |
---|---|
US (1) | US9867841B2 (es) |
EP (1) | EP2928476B1 (es) |
JP (2) | JP6392773B2 (es) |
CN (1) | CN104837492B (es) |
AU (1) | AU2013355238B2 (es) |
CA (1) | CA2891514C (es) |
CY (1) | CY1120201T1 (es) |
DK (1) | DK2928476T3 (es) |
ES (1) | ES2668045T3 (es) |
HU (1) | HUE038423T2 (es) |
LT (1) | LT2928476T (es) |
PL (1) | PL2928476T3 (es) |
PT (1) | PT2928476T (es) |
SI (1) | SI2928476T1 (es) |
WO (1) | WO2014089269A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9109002B2 (en) * | 2011-12-22 | 2015-08-18 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
EP3227310B1 (en) | 2014-12-03 | 2019-07-31 | GlycoMimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
CN105524927A (zh) * | 2016-02-28 | 2016-04-27 | 汪晓明 | 一种用于造血干细胞分离的适配子及其试剂盒 |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
JP7069136B2 (ja) | 2016-10-07 | 2022-05-17 | グリコミメティクス, インコーポレイテッド | 極めて強力な多量体e-セレクチンアンタゴニスト |
EP3596096A1 (en) | 2017-03-15 | 2020-01-22 | GlycoMimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
WO2019133878A1 (en) * | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
AU2019230013A1 (en) | 2018-03-05 | 2020-09-10 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
EP3893936A2 (en) * | 2018-12-10 | 2021-10-20 | GlycoMimetics, Inc. | Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
KR20220048007A (ko) | 2019-08-20 | 2022-04-19 | 글리코미메틱스, 인크. | E-셀렉틴 억제제 중간체의 제조 방법 |
AU2022221637A1 (en) | 2021-02-18 | 2023-08-17 | Glycomimetics, Inc. | Process for preparing an e-selectin inhibitor intermediate |
Family Cites Families (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7409399A (nl) | 1973-07-19 | 1975-01-21 | Rhone Poulenc Sa | Werkwijze ter bereiding van thermostabiele har- sen en voorwerpen geheel of gedeeltelijk be- staande uit deze harsen. |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4471057A (en) | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
DK17885D0 (da) | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | Antiviralt middel |
US4876199A (en) | 1985-04-04 | 1989-10-24 | Fred Hutchinson Cancer Research Center | Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain |
US4851511A (en) | 1986-01-30 | 1989-07-25 | Fred Hutchinson Cancer Research Center | Monoclonal antibody that specifically binds to disialosyl Lea |
US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
ES2058070T3 (es) | 1986-05-09 | 1994-11-01 | Pulverer Gerhard | Utilizacion de monosacaridos especificos para la preparacion de un medicamento para impedir metastasis de tumores malignos. |
US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
US5079353A (en) | 1987-12-02 | 1992-01-07 | Chembiomed, Ltd. | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5632991A (en) | 1988-11-14 | 1997-05-27 | Brigham & Women's Hospital | Antibodies specific for E-selectin and the uses thereof |
EP0381310A1 (en) | 1989-01-30 | 1990-08-08 | The Biomembrane Institute | Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof |
US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
EP0585963A1 (en) | 1989-05-23 | 1994-03-09 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies to CMP-170 antigen on activated endothelial cells |
US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US6001988A (en) | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
AU8007791A (en) | 1990-06-15 | 1992-01-07 | Cytel Corporation | Intercellular adhesion mediators |
US5753631A (en) | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
US5576305A (en) | 1990-06-15 | 1996-11-19 | Cytel Corporation | Intercellular adhesion mediators |
US6387884B1 (en) | 1990-06-18 | 2002-05-14 | Stanford University | Leukocyte homing modulation |
US6391857B1 (en) | 1990-06-18 | 2002-05-21 | Stanford University | Methods and compositions for endothelial binding |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
CA2086323C (en) | 1990-07-17 | 2002-05-14 | Rodger P. Mcever | Functionally active selectin-derived peptides and ligand for gmp-140 |
US5211937A (en) | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5143712A (en) | 1990-07-30 | 1992-09-01 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5648344A (en) | 1990-07-30 | 1997-07-15 | Glycomed Incorporated | Methods of treating inflammation using selection binding compounds |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
NZ240316A (en) | 1990-10-25 | 1996-12-20 | Univ Michigan | Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells |
EP0640129A1 (en) | 1990-11-23 | 1995-03-01 | The General Hospital Corporation | Inhibition of cell adhesion protein-carbohydrate interactions |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6121233A (en) | 1991-04-19 | 2000-09-19 | John L. Magnani | Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
US5318890A (en) | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
EP0584229B1 (en) | 1991-05-06 | 2003-07-23 | Genentech, Inc. | A selectin ligand |
US5352670A (en) | 1991-06-10 | 1994-10-04 | Alberta Research Council | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides |
US5646123A (en) | 1991-06-10 | 1997-07-08 | Alberta Research Council | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen |
US5580858A (en) | 1991-06-10 | 1996-12-03 | Alberta Research Council | Immunosuppressive and tolerogenic modified Lewisx compounds |
EP0608260A1 (en) | 1991-09-10 | 1994-08-03 | Centocor, Inc. | Peptide inhibitors of inflammation mediated by selectins |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5268364A (en) | 1991-12-12 | 1993-12-07 | The Biomembrane Institute | Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification |
CA2104099A1 (en) | 1991-12-18 | 1993-06-19 | George A. Heavner | Peptide inhibitors of inflammation mediated by selectins |
US5591835A (en) | 1992-06-29 | 1997-01-07 | Glycomed Incorporated | Substituted lactose derivatives |
CA2100412A1 (en) | 1992-07-15 | 1994-01-16 | Yutaka Yamada | Glycolipid derivatives |
US5753617A (en) | 1992-09-08 | 1998-05-19 | Centocor, Inc. | Peptide inhibitors of cellular adhesion |
US5519008A (en) | 1992-09-10 | 1996-05-21 | Glycomed Incorporated | Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin) |
US5695752A (en) | 1992-09-11 | 1997-12-09 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
WO1994006442A1 (en) | 1992-09-11 | 1994-03-31 | The Regents Of The University Of California | Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
EP0601417A3 (de) | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung |
WO1994014836A1 (en) | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
JP3887011B2 (ja) | 1992-12-29 | 2007-02-28 | ジェネンテク,インコーポレイテッド | IFN−γインヒビターによる炎症性腸疾患の処置 |
US5412123A (en) | 1993-02-08 | 1995-05-02 | Glycomed Incorporated | Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system |
US5763413A (en) | 1993-03-04 | 1998-06-09 | Mect Corporation | Lewis-associated compound, process for producing the same, and anti-inflammatory |
US5854064A (en) | 1996-07-31 | 1998-12-29 | Aphios Corporation | Methods for fractionation of biologically-derived materials |
US5527890A (en) | 1993-04-16 | 1996-06-18 | Glycomed Incorporated | Derivatives of triterpenoid acids and uses thereof |
US5854218A (en) | 1993-05-14 | 1998-12-29 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
SE9301677L (sv) | 1993-05-14 | 1994-11-18 | Kurt G I Nilsson | Syntesmetod |
HUT74506A (en) | 1993-05-14 | 1997-01-28 | Cytel Corp | Sialyl lewis-x analogues as inhibitors of cellular adhesion |
US5527785A (en) | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
US5811404A (en) | 1993-05-14 | 1998-09-22 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
ATE215094T1 (de) | 1993-05-17 | 2002-04-15 | Avant Immunotherapeutics Inc | Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen |
US5976540A (en) | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5646248A (en) | 1993-06-08 | 1997-07-08 | La Jolla Cancer Research Foundation | E-selection binding soluble lamp-1 polypeptide |
US5750508A (en) | 1993-06-16 | 1998-05-12 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5837689A (en) | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5789385A (en) | 1993-06-16 | 1998-08-04 | Glycomed Incorporated | Sialyl Lewisx mimetics containing phenyl backbones |
US5658880A (en) | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5679321A (en) | 1993-06-17 | 1997-10-21 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
DK76193D0 (da) | 1993-06-25 | 1993-06-25 | Astra Ab | Kulhydratderivater |
US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5508387A (en) | 1993-08-04 | 1996-04-16 | Glycomed Incorporated | Selectin binding glycopeptides |
US5827837A (en) | 1993-08-20 | 1998-10-27 | The Regents Of The University Of California | Polyanion anti-inflammatory agents |
US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
JPH09504522A (ja) | 1993-10-12 | 1997-05-06 | グリコメド・インコーポレイテッド | 細胞接着インヒビターの同定に有用なグリコ−ペプチドのライブラリー |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5783693A (en) | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
US5663151A (en) | 1994-03-04 | 1997-09-02 | Bristol-Myers Squibb Company | Sulfated α-glycolipid derivatives as cell adhesion inhibitors |
DE4408248A1 (de) | 1994-03-11 | 1995-09-14 | Hoechst Ag | Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung |
EP0671409A3 (de) | 1994-03-11 | 1996-06-12 | Hoechst Ag | Malonsäurederivate mit antiadhäsiven Eigenschaften. |
HUT77345A (hu) | 1994-04-29 | 1998-03-30 | Texas Biotechnology Corporation | E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények |
US5444050A (en) | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
US5486536A (en) | 1994-08-15 | 1996-01-23 | The Regents Of The University Of Michigan | Sulfatides as anti-inflammatory compounds |
JPH0899989A (ja) | 1994-09-30 | 1996-04-16 | Akira Hasegawa | 新規糖脂質誘導体およびその製造用中間体 |
DE4436164A1 (de) | 1994-10-10 | 1996-04-11 | Hoechst Ag | Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion |
US5686426A (en) | 1994-11-17 | 1997-11-11 | Bristol-Myers Squibb Company | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US5639734A (en) | 1994-12-20 | 1997-06-17 | Esko; Jeffrey D. | Disaccharide inflammation inhibitors and uses thereof |
CN1176644A (zh) | 1994-12-28 | 1998-03-18 | 住友制药株式会社 | 路易斯x衍生物及其制备方法 |
US20020040008A1 (en) | 1995-01-24 | 2002-04-04 | Wagner Denisa D. | Method for treating and preventing atherosclerosis |
US5527936A (en) | 1995-02-17 | 1996-06-18 | E. I. Du Pont De Nemours And Company | Hydrosilylation of unsaturated compounds |
GB9504065D0 (en) | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Poly-pyrrolecarboxamidonaphthalenic acid derivatives |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
US5736533A (en) | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
PL185372B1 (pl) | 1995-06-29 | 2003-04-30 | Texas Biotechnology Corp | Inhibitory selektyny i kompozycja farmaceutyczna |
SI9620099A (sl) | 1995-06-29 | 1998-08-31 | Novartis Ag | Diglikozilirani 1,2-dioli kot mimetiki sialil-Lewis X in sialil-Lewis A |
US5876715A (en) | 1995-08-17 | 1999-03-02 | The Biomembrane Institute | Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof |
DE19532902A1 (de) | 1995-09-06 | 1997-03-13 | Hoechst Ag | Neuartige Glycomimetika als Selektin-Antagonisten und daraus hergestellte entzündungshemmend wirkende Arzneimittel |
DE19537334A1 (de) | 1995-10-09 | 1997-04-10 | Hoechst Ag | Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren |
AU7445796A (en) | 1995-10-18 | 1997-05-07 | Cytel Corporation | Sialyl lex analogues as inhibitors of cellular adhesion |
US5919769A (en) | 1995-10-26 | 1999-07-06 | Kanebo, Ltd | Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same |
US5747463A (en) | 1995-11-13 | 1998-05-05 | Bristol-Myers Squibb Company | Malonate derivatives of glycolipids as cell adhesion inhibitors |
JPH09176047A (ja) | 1995-12-25 | 1997-07-08 | Unitika Ltd | 外用医薬製剤 |
DE19602355A1 (de) | 1996-01-24 | 1997-07-31 | Hoechst Ag | Mehrfach fucosylierte Dicarbonsäuren mit antiadhäsiven Eigenschaften |
WO1997028173A1 (en) | 1996-01-30 | 1997-08-07 | Novartis Ag | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES |
DE69738731D1 (de) | 1996-01-30 | 2008-07-10 | Glycomimetics Inc | SIALYL-LEWISa UND SIALYL-LEWISx EPITOPE ANALOGE |
DE69712754T2 (de) | 1996-03-01 | 2002-10-17 | Univ California | Hemmung der selectinbindung |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US6344545B1 (en) | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US5654412A (en) | 1996-05-29 | 1997-08-05 | Glycomed Incorporated | Processes for the synthesis of sialyl Lewisx compounds |
CA2197058A1 (en) | 1996-06-05 | 1997-12-06 | Avery B. Nathens | Anti-inflammatory agent |
US5919768A (en) | 1996-06-26 | 1999-07-06 | Texas Biotechnology Corporation | Di- and trivalent small molecule selectin inhibitors |
WO1998006730A1 (en) | 1996-08-08 | 1998-02-19 | Novartis Ag | Modified oligosaccharides |
US5830871A (en) | 1996-10-28 | 1998-11-03 | The Scripps Research Institute | Inhibitors of E-, P- and L-selectin binding |
GB9618520D0 (en) | 1996-09-05 | 1996-10-16 | Chiroscience Ltd | Compounds and their therapeutic use |
US6592872B1 (en) | 1996-09-17 | 2003-07-15 | The United States Of America As Represented By The Department Of Health And Human Services | Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein |
AU4594297A (en) | 1996-09-27 | 1998-04-17 | Trustees Of Columbia University In The City Of New York, The | Methods for treating an ischemic disorder and improving stroke outcome |
DE69718341T2 (de) | 1996-10-08 | 2003-10-30 | Bisys B V U | Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül |
US6110897A (en) | 1996-10-10 | 2000-08-29 | Glycorex Ab | Antiinflammatory cell adhesion inhibitors |
US6043348A (en) | 1996-11-13 | 2000-03-28 | Lawman; Michael J. P. | Antibody recognizing a small subset of human hematopoietic cells |
AU733692B2 (en) | 1997-02-28 | 2001-05-24 | Regents Of The University Of California, The | Inhibition of cell-cell binding by lipid assemblies |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
SE9701127D0 (sv) | 1997-03-26 | 1997-03-26 | Karolinska Innovations Ab | Antigenic fusionprotein carrying GALal, 3GAL epitopes |
JP3720520B2 (ja) | 1997-03-27 | 2005-11-30 | タカラバイオ株式会社 | 糖と標的物との相互作用の測定方法 |
US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
US6193973B1 (en) | 1997-08-22 | 2001-02-27 | B. David Tuttle | Dietary supplement for boosting energy and increasing muscular strength |
US5948628A (en) | 1997-09-05 | 1999-09-07 | The Board Of Regents Of The University Of Oklahoma | Methods of screening for compounds which mimic galectin-1 |
US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
WO1999043356A1 (en) | 1998-02-25 | 1999-09-02 | Hsc Research Development Limited Partnership | Antibiotic-ligand conjugates and methods of use thereof |
WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
US6458777B1 (en) | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
US6365365B1 (en) | 1998-03-20 | 2002-04-02 | The Regents Of The University Of California | Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
US6265192B1 (en) | 1998-03-20 | 2001-07-24 | The Regents Of The University Of California | Glycosly sulfortransferase-3 |
US6037333A (en) | 1998-05-07 | 2000-03-14 | Trustees Of Tufts College | Microbe-inhibiting compositions |
CA2330611A1 (en) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and therapies based thereon |
WO1999065712A2 (en) | 1998-06-16 | 1999-12-23 | The Board Of Regents Of The University Of Oklahoma | Glycosulfopeptides and methods of synthesis and use thereof |
US6004815A (en) | 1998-08-13 | 1999-12-21 | The Regents Of The University Of California | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
US6503885B1 (en) | 1998-09-21 | 2003-01-07 | Otsuka Pharmaceutical Co., Ltd. | Carboxymethylgalactose derivatives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6960566B1 (en) | 1998-11-06 | 2005-11-01 | The Wister Institute of Anatomy and Biology | Compositions and methods for treatment of cancer |
EP1131106B1 (en) | 1998-11-12 | 2009-06-24 | Novolytics Inc. | Compositions and methods for producing vascular occlusion |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6887842B1 (en) | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
DE60118362T2 (de) | 2000-05-19 | 2007-05-24 | The Center for Blood Research, Inc., Boston | VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN |
AU2000274809A1 (en) | 2000-09-12 | 2002-03-26 | Genetics Institute Llc | Inhibition of stenosis or restenosis by p-selectin antagonists |
US7709461B2 (en) | 2000-10-18 | 2010-05-04 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
AU2002219828A1 (en) | 2000-11-14 | 2002-05-27 | The General Hospital Corporation | Blockade of T cell migration into epithelial GVHD target tissues |
US7422733B2 (en) | 2000-11-29 | 2008-09-09 | Bracco International B.V. | Linkable sialyl Lewis X analogs |
US20020132220A1 (en) | 2000-12-27 | 2002-09-19 | Berens Kurt L. | Use of selectin antagonists in organ preservation solutions |
EP1536828B1 (en) | 2001-03-28 | 2013-06-05 | President and Fellows of Harvard College | Methods for delivery of exogenous proteins to the cytosol |
US20030198639A1 (en) | 2002-04-16 | 2003-10-23 | Frenette Paul S. | Methods of treating sickle cell disease |
US7087212B2 (en) | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
AU2002357072A1 (en) | 2001-12-07 | 2003-06-23 | Centocor, Inc. | Pseudo-antibody constructs |
MXPA04006136A (es) | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
US20030186942A1 (en) | 2002-01-16 | 2003-10-02 | Crooks Peter A. | Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders |
EP1492724A1 (en) | 2002-04-09 | 2005-01-05 | Gyros AB | Microfluidic devices with new inner surfaces |
US20040072796A1 (en) | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
US7060725B2 (en) | 2002-05-13 | 2006-06-13 | Janssen Pharmaceutica N.V. | Substituted sulfamate anticonvulsant derivatives |
JP5183010B2 (ja) | 2002-05-16 | 2013-04-17 | グリコミメティクス, インコーポレイテッド | セレクチンによって媒介される機能を阻害するための化合物および方法 |
CA2490703A1 (en) | 2002-07-03 | 2004-01-15 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
AU2003282821B2 (en) | 2002-10-11 | 2010-12-16 | University Of Maryland, Baltimore | Carbohydrate-based synthetic vaccines for HIV |
EP1575619A1 (en) | 2002-12-20 | 2005-09-21 | Glycomimetics, Inc. | Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection |
US7332334B2 (en) | 2003-04-18 | 2008-02-19 | Oklahoma Medical Research Foundation | Hematopoietic stem cells treated by in vitro fucosylation and methods of use |
US20040219158A1 (en) | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
CA2544598A1 (en) | 2003-11-07 | 2005-05-26 | Brigham And Women's Hospital, Inc. | Antibodies to cd44 glycoforms and uses thereof |
ATE383367T1 (de) | 2003-11-19 | 2008-01-15 | Glycomimetics Inc | Spezifischer antagonist sowohl für e- als auch p- selektine |
JP2007524658A (ja) | 2003-11-19 | 2007-08-30 | グリコミメティクス, インコーポレイテッド | E−およびp−セレクチンの両方のための糖模倣物アンタゴニスト |
AU2004299267A1 (en) | 2003-12-18 | 2005-06-30 | Unibioscreen S.A. | Glycosylated steroid derivatives with anti-migratory activity |
GB0404434D0 (en) | 2004-02-27 | 2004-03-31 | Novartis Ag | Organic compounds |
WO2005116088A2 (en) | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
CA2571431A1 (en) | 2004-06-24 | 2006-01-05 | The Scripps Research Institute | Arrays with cleavable linkers |
WO2006017180A2 (en) | 2004-07-09 | 2006-02-16 | Progenics Pharmaceuticals, Inc. | Glycopeptide dimers and uses thereof |
TW200616968A (en) | 2004-08-27 | 2006-06-01 | Ono Pharmaceutical Co | Compound having basic substituent and application thereof |
WO2006062946A2 (en) | 2004-12-06 | 2006-06-15 | University Of Florida Research Foundation, Inc. | Incorporation of bone marrow derived stem cells in tumors |
MX2007008326A (es) | 2005-01-07 | 2008-01-16 | Univ Emory | Antagonistas de cxcr4 para el tratamiento de una infeccion por vih. |
MX2007008328A (es) | 2005-01-07 | 2008-01-16 | Univ Emory | Antagonistas cxcr4 para el tratamiento de trastornos medicos. |
EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
US20060217303A1 (en) | 2005-03-25 | 2006-09-28 | Wisconsin Alumni Research Foundation | Compounds and Methods for Treating Seizure Disorders |
WO2006127906A1 (en) | 2005-05-25 | 2006-11-30 | Glycomimetics, Inc. | Heterobifunctional compounds for selectin inhibition |
US20060287253A1 (en) | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
AU2006272780A1 (en) | 2005-07-22 | 2007-02-01 | The Regents Of The University Of California | Heparin compostions and selectin inhibition |
ES2375979T3 (es) | 2005-08-09 | 2012-03-07 | Glycomimetics, Inc. | Inhibidores glicomiméticos de la lectina pa-il, lectina pa-iil o ambas lectinas de pseudomonas. |
EP1929313A2 (en) | 2005-08-15 | 2008-06-11 | The Scripps Research Institute | Methods to identify therapeutic agents |
WO2007022385A2 (en) | 2005-08-18 | 2007-02-22 | Novartis Ag | Use of cxcr4 binding molecules for the treatment of whim syndrome |
CN103626813B (zh) * | 2005-09-02 | 2017-05-03 | 糖模拟物有限公司 | 异型双功能全选择素抑制剂 |
EP1937308A4 (en) | 2005-09-14 | 2010-09-15 | Univ Maryland Biotech Inst | SYNTHETIC ADDED CARBOHYDRATES AS INGREDIENTS OF MICROBICIDES |
WO2007143052A1 (en) | 2006-06-01 | 2007-12-13 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
WO2007146188A2 (en) | 2006-06-07 | 2007-12-21 | The Board Of Trustees Of The Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
WO2008002449A2 (en) | 2006-06-23 | 2008-01-03 | Glycomimetics, Inc. | Glycomimetic inhibitors of siglec-8 |
WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
US20080227799A1 (en) | 2006-07-11 | 2008-09-18 | Liotta Dennis C | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders |
US7998740B2 (en) | 2006-07-18 | 2011-08-16 | Robert Sackstein | Cytokine induction of selectin ligands on cells |
JP5298020B2 (ja) | 2006-10-12 | 2013-09-25 | グリコミメティクス, インコーポレイテッド | ヘキソースおよびn−アセチルヘキソサミンの糖模倣体置換 |
US20080306098A1 (en) | 2006-11-06 | 2008-12-11 | Mutz Mitchell W | Pharmacokinetics of protease inhibitors and other drugs |
US20100145032A1 (en) | 2007-01-18 | 2010-06-10 | Suomen Punainen Risti, Veripalelu | Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof |
CA2677747A1 (en) | 2007-02-09 | 2008-08-21 | Glycomimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
WO2008109154A1 (en) | 2007-03-08 | 2008-09-12 | Altiris Therapeutics, Inc. | Chemokine receptor modulators |
US20090054334A1 (en) | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
KR20100042654A (ko) | 2007-08-08 | 2010-04-26 | 교와 핫꼬 기린 가부시키가이샤 | 단리된 세포 집단 |
US20100215575A1 (en) | 2007-10-12 | 2010-08-26 | Transmolecular, Inc. | Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors |
FI20070853A0 (fi) | 2007-11-09 | 2007-11-09 | Glykos Finland Oy | Glykaania sitovat monoklonaaliset vasta-aineet |
AU2008336249B2 (en) | 2007-12-10 | 2015-01-29 | The University Of Queensland | Treatment and prophylaxis |
WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
EP2318015B1 (en) | 2008-06-13 | 2013-08-07 | GlycoMimetics, Inc. | Treatment of cancers of the blood using selected glycomimetic compounds |
US20100240773A1 (en) | 2009-03-23 | 2010-09-23 | Kenneth Korzekwa | Multifunctional linkers |
FI20095459A0 (fi) | 2009-04-24 | 2009-04-24 | Suomen Punainen Risti Veripalv | Uusia määritysmenetelmiä |
JP5726171B2 (ja) * | 2009-05-01 | 2015-05-27 | グリコミメティックス インコーポレイテッド | E−セレクチンおよびcxcr4ケモカイン受容体のヘテロ二官能性阻害剤 |
WO2010132315A1 (en) | 2009-05-13 | 2010-11-18 | Endgenitor Technologies, Inc. | Enhanced hematopoietic stem cell engraftment |
EP2555779A1 (en) | 2010-04-07 | 2013-02-13 | GlycoMimetics, Inc. | Glycomimetic compounds and methods to inhibit infection by hiv |
WO2012037034A1 (en) | 2010-09-14 | 2012-03-22 | Glycomimetics, Inc. | E-selectin antagonists |
US20130261070A1 (en) | 2010-10-04 | 2013-10-03 | John L. Magnani | Anti-epileptogenic agents |
WO2012061662A1 (en) * | 2010-11-03 | 2012-05-10 | Glycomimetics, Inc. | Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors |
TWI497333B (zh) | 2011-06-14 | 2015-08-21 | Giant Mfg Co Ltd | 自行車適配產生方法、自行車適配系統與電腦程式產品 |
US9109002B2 (en) * | 2011-12-22 | 2015-08-18 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
US9104666B2 (en) | 2012-09-04 | 2015-08-11 | Oracle International Corporation | Controlling access to a large number of electronic resources |
US20150284420A1 (en) | 2012-10-31 | 2015-10-08 | Glycomimetics, Inc. | E-selectin antagonist compounds and methods of use |
WO2014149837A1 (en) | 2013-03-15 | 2014-09-25 | Glycomimetics, Inc. | Compounds and methods to enhance the oral availability of glycomimetics |
EP3052510A4 (en) | 2013-09-30 | 2017-03-29 | GlycoMimetics, Inc. | Methods and compositions for treating and/or preventing mucositis |
-
2013
- 2013-12-05 ES ES13811325.3T patent/ES2668045T3/es active Active
- 2013-12-05 US US14/650,102 patent/US9867841B2/en active Active
- 2013-12-05 CA CA2891514A patent/CA2891514C/en active Active
- 2013-12-05 PT PT138113253T patent/PT2928476T/pt unknown
- 2013-12-05 WO PCT/US2013/073258 patent/WO2014089269A1/en active Application Filing
- 2013-12-05 CN CN201380063752.6A patent/CN104837492B/zh active Active
- 2013-12-05 SI SI201331017T patent/SI2928476T1/en unknown
- 2013-12-05 JP JP2015545831A patent/JP6392773B2/ja active Active
- 2013-12-05 HU HUE13811325A patent/HUE038423T2/hu unknown
- 2013-12-05 LT LTEP13811325.3T patent/LT2928476T/lt unknown
- 2013-12-05 DK DK13811325.3T patent/DK2928476T3/en active
- 2013-12-05 PL PL13811325T patent/PL2928476T3/pl unknown
- 2013-12-05 EP EP13811325.3A patent/EP2928476B1/en active Active
- 2013-12-05 AU AU2013355238A patent/AU2013355238B2/en active Active
-
2018
- 2018-02-23 JP JP2018030634A patent/JP2018087240A/ja not_active Withdrawn
- 2018-05-07 CY CY20181100478T patent/CY1120201T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013355238A1 (en) | 2015-06-04 |
AU2013355238B2 (en) | 2017-12-14 |
CY1120201T1 (el) | 2018-12-12 |
EP2928476A1 (en) | 2015-10-14 |
EP2928476B1 (en) | 2018-02-14 |
JP2018087240A (ja) | 2018-06-07 |
CA2891514C (en) | 2020-08-25 |
JP6392773B2 (ja) | 2018-09-19 |
CA2891514A1 (en) | 2014-06-12 |
LT2928476T (lt) | 2018-05-25 |
US20160184339A1 (en) | 2016-06-30 |
DK2928476T3 (en) | 2018-05-22 |
US9867841B2 (en) | 2018-01-16 |
SI2928476T1 (en) | 2018-06-29 |
CN104837492B (zh) | 2018-04-27 |
HUE038423T2 (hu) | 2018-10-29 |
WO2014089269A1 (en) | 2014-06-12 |
CN104837492A (zh) | 2015-08-12 |
JP2016506386A (ja) | 2016-03-03 |
PT2928476T (pt) | 2018-05-10 |
PL2928476T3 (pl) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2668045T3 (es) | Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas | |
Pelus | Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand | |
Pusic et al. | Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells | |
Müller et al. | Hematopoietic stem cells in regenerative medicine: astray or on the path? | |
US20180346877A1 (en) | Natural killer cells and ilc3 cells and uses thereof | |
JP2017535610A5 (es) | ||
US20230028680A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
NZ733213A (en) | Natural killer cells and uses thereof | |
AU2015362089B2 (en) | Dislodgement and release of HSC using alpha 9 integrin antagonist and CXCR4 antagonist | |
WO2014134539A1 (en) | Methods and compositions for mobilizing stem cells | |
EP2214670A2 (en) | Compounds for treating abnormal cellular proliferation | |
RU2009108289A (ru) | Комбинированная терапия | |
US20190093081A1 (en) | Placenta-derived intermediate natural killer (pink) cells for treatment of glioblastoma | |
CA3110964A1 (en) | Preventing a symptom of graft-versus-host disease using human placenta-derived intermediate natural killer cells | |
KR20170118700A (ko) | (1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도 | |
JP7168552B2 (ja) | 造血幹細胞・前駆細胞の作製、増殖および分化のための置換アゾール誘導体 | |
Liang et al. | The role of bone marrow stromal cells in blood diseases and clinical significance as a crucial part of the hematopoietic microenvironment | |
WO2021022229A1 (en) | Populations of natural killer cells comprising a cleavage resistant cd16 | |
US20130338183A1 (en) | Compositions and methods for mobilizing stem cells | |
KR20170109541A (ko) | 알파9 인테그린 길항제를 사용한 골수 줄기 세포 니치로부터의 hsc의 이탈 및 방출 | |
Broxmeyer et al. | Cord blood transplantation: state of the science | |
US20220125844A1 (en) | Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy | |
US20220000919A1 (en) | Placental derived natural killer cells for treatment of coronavirus infections | |
Konenkov et al. | Phenotype of peripheral blood cells mobilized by granulocyte colony-stimulating factor in patients with chronic heart failure | |
Jargin | Stem cells and cell therapy: Sober view |